Your fact-checks will appear here
Peer-reviewed scientific journal
Only a single actively registered randomized or early-phase trial of ivermectin in human cancer patients is clearly documented in the available reporting: a phase I/II study combining oral ivermectin ...
European investigators have moved ivermectin from petri dishes into a very small number of human studies, but robust evidence of benefit in cancer is lacking: a 2025 ASCO abstract reported a phase I/I...
Drug–drug interactions and P‑glycoprotein (P‑gp) considerations have been raised in reviews of ivermectin’s repositioning for cancer, but available clinical evidence in cancer patients is sparse and m...
European clinical-trial registries and recent reviews show almost no completed European trials testing ivermectin as a cancer therapy; most human work is preclinical and the only active clinical progr...
As of 2025, ClinicalTrials.gov shows a single registered interventional study testing ivermectin for cancer: a Phase I/II trial (NCT05318469) combining oral ivermectin with an immune checkpoint inhibi...
U.S. and EU regulators do not approve ivermectin or similar antiparasitics for cancer and repeatedly warn against off‑label use outside clinical trials; there are numerous preclinical studies but no c...
You can find case series and pharmacovigilance reports about ivermectin use in oncology mainly in reviews and small case compilations, pharmacovigilance project papers, and news/meeting abstracts — bu...
Yes — hundreds to thousands of peer‑reviewed cannabis studies are being published now: advocacy tallies say more than 4,000 cannabis papers appeared in 2025 and PubMed lists “over 57,000” marijuana‑re...
Medicaid’s budget directly shapes healthcare access and outcomes for low-income families by determining eligibility, benefits, and the balance of federal versus state financing; . Researchers also fin...